Woodline Partners’s Climb Bio CLYM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$31.3M Buy
2,731,469
+1,149,178
+73% +$16M 0.09% 284
2026
Q2
$20.6M Buy
+1,582,291
New +$16.3M 0.06% 359
2024
Q3
– Sell
-22,192
Closed -$158K – 726
2024
Q2
$158K Buy
+22,192
New +$148K ﹤0.01% 536
2022
Q4
– Sell
-226,604
Closed -$732K – 858
2022
Q3
$732K Sell
226,604
-146,764
-39% -$468K 0.01% 559
2022
Q2
$1.13M Hold
373,368
– – 0.02% 503
2022
Q1
$3.13M Hold
373,368
– – 0.05% 305
2021
Q4
$3.9M Sell
373,368
-13,856
-4% -$207K 0.06% 316
2021
Q3
$6.96M Buy
+387,224
New +$8M 0.11% 214

Other funds holding CLYM

Woodline Partners's CLYM Position: Q3 2026 in Review

Woodline Partners increased its Climb Bio (CLYM) stake by 73% in Q3 2026, buying an estimated $16M and bringing the position to 2,731,469 shares worth $31.3M. The position accounts for 0.09% of the portfolio, ranked #284.

Woodline Partners first reported a position in CLYM in Q3 2021 and has held it in 8 quarters since. 128 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.

  • Woodline Partners held 2,731,469 shares of Climb Bio worth $31.3M as of Q3 2026.
  • Woodline Partners bought 1,149,178 Climb Bio shares in Q3 2026, an estimated $16M.
  • Climb Bio made up 0.09% of Woodline Partners's portfolio in Q3 2026, its #284 holding.
  • Woodline Partners first reported a position in Climb Bio in Q3 2021 and has held it in 8 quarters since.
  • 128 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.